
Rebecka Hellsten

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4184267/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Galiellalactone Inhibits Stem Cell-Like ALDH-Positive Prostate Cancer Cells. PLoS ONE, 2011, 6, e22118.	2.5	81
2	Galiellalactone Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells. Journal of Biological Chemistry, 2014, 289, 15969-15978.	3.4	78
3	Expression of STAT3 in Prostate Cancer Metastases. European Urology, 2017, 71, 313-316.	1.9	78
4	Galiellalactone is a novel therapeutic candidate against hormoneâ€refractory prostate cancer expressing activated Stat3. Prostate, 2008, 68, 269-280.	2.3	75
5	Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS ONE, 2017, 12, e0184418.	2.5	58
6	The STAT3 inhibitor galiellalactone inhibits the generation of MDSCâ€ ŀ ike monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors. Prostate, 2019, 79, 1611-1621.	2.3	47
7	The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer. European Urology, 2016, 69, 400-404.	1.9	43
8	Preclinical Characterization of 3β-(<i>N</i> -Acetyl <scp>l</scp> -cysteine methyl) Tj ETQq0 0 0 rgBT /Overlock 10 Prostate Cancer. Journal of Medicinal Chemistry, 2016, 59, 4551-4562.) Tf 50 467 6.4	7 Td (ester)-2 30
9	STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population. Scientific Reports, 2020, 10, 13958.	3.3	20
10	The fungal metabolite galiellalactone interferes with the nuclear import of NF-κB and inhibits HIV-1 replication. Chemico-Biological Interactions, 2014, 214, 69-76.	4.0	14
11	Therapeutic Targeting of Nuclear Î ³ -Tubulin in RB1-Negative Tumors. Molecular Cancer Research, 2015, 13, 1073-1082.	3.4	13
12	Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer. Cancer Immunology, Immunotherapy, 2021, 70, 3155-3166.	4.2	13
13	Cytokines and Janus kinase/signal transducer and activator of transcription signaling in prostate cancer: overview and therapeutic opportunities. Current Opinion in Endocrine and Metabolic Research, 2020, 10, 36-42.	1.4	11
14	Expression of tSTAT3, pSTAT3 727 , and pSTAT3 705 in the epithelial cells of hormoneâ€naÃ⁻ve prostate cancer. Prostate, 2019, 79, 784-797.	2.3	8
15	N-Conjugate prodrugs of galiellalactone. Tetrahedron Letters, 2016, 57, 4090-4093.	1.4	3
16	Nuclear expression of pSTAT3Tyr705 and pSTAT3Ser727 in the stromal compartment of localized hormone-naÃīve prostate cancer. Pathology Research and Practice, 2022, 232, 153811.	2.3	2